Compare Extra Space Storage, Inc. (EXR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Mesoblast Limited — how do they compare? Extra Space Storage, Inc. trades at $134.65 (market cap $28.12B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Extra Space Storage, Inc. is far larger — about 16.1× Mesoblast Limited's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Mesoblast Limited for 15 Days on average.
| EXR | MESO | |
|---|---|---|
Market Cap | $28.12B | $1.75B |
Volume | 2,595,579 | 239,027 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $20.96 |
52-Week Low | $126.67 | $13.19 |
Typical Hold Time | 109 Days | 15 Days |
Enterprise Value | $41.84B | $1.83B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $133.12, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin remains healthy at 27.79%. Analyst consensus is split evenly between Buy and Hold, with a price target of $158.33 implying upside. Recent news highlights leadership transition and positive operational performance.
The outlook is balanced: solid profitability and growth support upside, but high valuation multiples and bearish technicals pose near-term risks. Key catalysts include Q3 earnings and execution under new leadership. Risks involve interest rate sensitivity and competitive pressures in the REIT sector.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
